Abstract: This field study of feral stallions in Montana and Idaho examines and correlates the seasonal pattern of plasma androgens and specific sociosexual behaviour and reports the effect of a long-acting androgenic steroid on this behaviour and on fertility. Plasma testosterone was measured by competitive protein binding assay in samples obtained by jugular venepuncture from captured animals. In samples taken from 34 sexually mature stallions in 6 different months during the year, a definite seasonal pattern in testosterone was present, with a peak in May (3.04 +/- 0.63 ng/ml) and a nadir in December (1.55 +/- 0.34 ng/ml). Values were less than 2.0 ng/ml in non-breeding months and greater than 2.4 ng/ml in breeding months. Behavioural endpoints measured were (1) stallion scent marking in response to elimination by mares (elimination marking), (2) mounting and (3) copulation. The frequencies of each of these endpoints followed closely the seasonal pattern seen for plasma androgens. In the fertility study microcapsulated testosterone propionate (microTP) was administered i.m. to 10 harem stud stallions 3 months before the 1980 breeding season. In these stallions and in 10 control harem studs, the above behavioural endpoints were examined in the 1980 and 1981 breeding seasons, and foal counts were made in 1981. There were no direct inhibitory or stimulatory effects of microTP treatment on any of the behavioural endpoints in either year. In 1981 foals were produced in 87.5% of the control bands and 28.4% of the microTP-treated bands. These results indicate that microencapsulated testosterone propionate can provide effective fertility control in feral horses without causing significant alterations in sociosexual behaviour.

Abstract: Contraception is becoming a common approach for the management of captive and wild ungulates yet there are few data for contraceptive effects on entire populations. Management-level treatment of mares with porcine zona pellucida (PZP) vaccine resulted in zero population growth of the Assateague Island wild horse population within 1 year of initiation of treatment. Contraceptive efficacy was 90% for mares treated twice in the first year and annually thereafter. For mares given a single initial inoculation, contraceptive efficacy was 78%. The effort required to achieve zero population growth decreased, as 95, 83 and 84% of all adult mares were treated in each of the first 3 years, compared with 59 and 52% during the last 2 years. Mortality rates for mares and foals after the initiation of management-level treatments decreased below historic and pretreatment mortality rates of approximately 5%. Two new age classes have appeared among treated animals (21-25 years and > 25 years), indicating an increase in longevity among treated animals. Body condition scores for all horses, all adult mares and non-lactating mares increased significantly between summer 1989 and autumn 1999 but did not change significantly in lactating mares. These results provide reliable data for the construction of realistic models for contraceptive management of free-roaming or captive ungulate populations.

Abstract: African horse sickness (AHS) is an infectious but no-contagious viral disease of equidae with high mortality in horses. The disease is caused by an arthropod-borne double-stranded RNA virus within the genus Orbivirus of the family Reoviridae transmitted by at least two species of Culicoides. Nine different serotypes have been described. The nine serotypes of AHS have been described in eastern and southern Africa. Only AHS serotypes 9 and 4 have been found in West Africa from where they occasionally spread into countries surrounding the Mediterranean. Examples of outbreaks that have occurred outside Africa are: in the Middle East (1959-1963), in Spain (serotype 9, 1966, serotype 4, 1987-1990), and in Portugal (serotype 4, 1989) and Morocco (serotype 4, 1989-1991). Laboratory diagnosis of AHS is essential. Although the clinical signs and lesions are characteristic, they can be confused with those of other diseases. Several techniques have been adapted for the detection of RNA segments, antibodies and antigen. Two types of vaccines have been described for AHS virus. Attenuated live vaccines (monovalent and polyvalent) for use in horses, mules and donkeys, are currently available, as well as a monovalent, serotype 4, inactivated vaccine, produced commercially but no longer available. New vaccines, including a subunit vaccine, have been evaluated experimentally. In this paper a review of the last AHS outbreaks in Spain, occurring during 1987-1990, and affecting the central and south part of the country, is presented. The role that vaccination played for the control and eradication of the disease, as well as other aspects such as climatological conditions, number of vectors and horse management, are also presented and evaluated.